Healthy
Conditions
Keywords
gastrointestinal health, healthy subjects
Brief summary
The investigational study product used in this clinical trial is a soft drink containing an arabinoxylan-oligosaccharides (AXOS) preparation extracted from wheat bran (hereafter called Wheat Bran Extract, WBE). The objective of this study is to analyze the effect of the intake of two WBE doses on various parameters of gastrointestinal health. Additionally, safety was analyzed using treatment emergent Adverse Events (AEs) and clinical blood parameters.
Interventions
DIETARY_SUPPLEMENTwheat bran extract
soft drink comprising high WBE dose and natural flavor and coloring agent, ingestion after breakfast and after dinner
DIETARY_SUPPLEMENTplacebo
soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and after dinner
Sponsors
Fugeia NV
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female 18-90 years of age, inclusive * Regular eating habits * Body Mass Index (BMI) between 18.5 and 30 kg/m2 * Consent to take in the study product according to the study protocol * Subject is willing to maintain his or her habitual food and beverage intake throughout the study period (with the exception of omission of prebiotic and probiotic food products as indicated in the study protocol) * For female volunteers of childbearing potential: not planning to become pregnant during the clinical trial and willing to commit to the use of a medically approved form of contraception
Exclusion criteria
* Low-calorie diet or other extreme dietary habits in the 6 weeks before the start of the clinical trial * Recent use of antibiotics * Abdominal surgery in the past * Serious illness within 3 months of start of clinical trial * Use of medication or dietary supplements known to influence GI tract within two weeks of start of clinical trial. Examples of such medication/dietary supplements are antispasmodics, anti diarrhea medication and/or probiotic medication * Complete anesthetics within 1 month of the start of the clinical trial * Chronic GI conditions such as inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), chronic constipation, history of frequent diarrhea, clinically important lactose intolerance * Allergy for wheat products * Celiac disease * For female volunteers: pregnant or lactating * Alcohol abuse * Smoking more than 5 cigarettes per day * Subject has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the subject at undue risk.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bifidobacteria content in feces | day 19 or 20 of each intervention |
| butyric acid content in feces | day 19 or 20 of each intervention |
| p-cresol content in urine | day 19-21 of each intervention |
| stool frequency | third week of each intervention |
Secondary
| Measure | Time frame |
|---|---|
| adverse events | whole study |
| clinical blood parameters | day 21 of each intervention |
Countries
Belgium
Outcome results
None listed